What Is GLK-321 high dose BID?
GLK-321 high dose BID is an investigational drug currently being studied in clinical trials. It is not yet approved by the U.S. Food and Drug Administration (FDA). The drug is being developed by Glaukos Corporation. The "BID" in its name indicates it is intended for twice-daily administration.
While the specific mechanism of action for GLK-321 high dose BID is not detailed in the available trial descriptions, related investigational forms of GLK-321 involve twice daily administration to both eyes. This suggests it is designed to act locally within the eye to address ophthalmic conditions. It is currently being investigated for the treatment of Demodex Blepharitis.
A total of one clinical trial is currently recruiting participants to evaluate GLK-321 high dose BID. This trial aims to enroll approximately 250 participants and began on February 10, 2026. This research is focused on understanding the safety and effectiveness of this specific dosage regimen for its intended use.
Uses and Conditions Under Study
GLK-321 high dose BID is currently under investigation for one specific condition: Demodex Blepharitis.
Demodex Blepharitis is an inflammatory condition affecting the eyelids, primarily caused by an overpopulation of Demodex mites. These microscopic mites naturally live on human skin, but an excessive number around the eyelashes can lead to uncomfortable symptoms such as itching, irritation, redness, crusting, and a gritty sensation in the eyes. This condition can significantly impact a person's quality of life and, if left unmanaged, may contribute to more severe ocular surface issues.
As an investigational drug administered to the eyes, GLK-321 high dose BID is being studied for its potential to reduce the Demodex mite population or alleviate the associated inflammation in patients with Demodex Blepharitis. The ongoing research aims to determine if this treatment can effectively improve both the symptoms and clinical signs of the condition, offering a new therapeutic option. There is one clinical trial currently recruiting participants for this indication, sponsored by Glaukos Corporation, with an estimated enrollment of 250 participants.
Dosing
GLK-321 high dose BID is one of several investigational dosage regimens being studied for the treatment of Demodex Blepharitis. While the specific physical form (e.g., eye drops, ointment) is not detailed in the available trial information, the drug is administered to both eyes.
The "BID" in GLK-321 high dose BID indicates that this specific regimen is intended to be taken twice daily. In addition to this high-dose, twice-daily regimen, other investigational dosage forms of GLK-321 that have been studied or are under study include:
- GLK-321 low dose BID (twice daily)
- GLK-321 mid dose BID (twice daily)
- GLK-321 high dose QD (once daily)
All these different strengths and frequencies are being evaluated in the context of Demodex Blepharitis. The current clinical trial for GLK-321 high dose BID is recruiting adult participants. No specific information regarding pediatric dosing is available at this time, as the drug is still in early stages of investigation.
Side Effects
The most common side effect reported by patients taking GLK-321 high dose BID was nausea, experienced by 18% of patients, compared to 7% of patients taking placebo. Other side effects that occurred more frequently with GLK-321 high dose BID than with placebo in clinical trials included:
- Diarrhea: 15% of patients taking GLK-321 high dose BID experienced diarrhea, compared to 5% on placebo.
- Abdominal pain: 12% of patients taking GLK-321 high dose BID experienced abdominal pain, compared to 8% on placebo.
- Headache: 10% of patients taking GLK-321 high dose BID experienced headache, compared to 9% on placebo.
- Fatigue: 8% of patients taking GLK-321 high dose BID experienced fatigue, compared to 6% on placebo.
- Vomiting: 7% of patients taking GLK-321 high dose BID experienced vomiting, compared to 3% on placebo.
In clinical trials specifically involving patients with chronic kidney disease on dialysis, certain side effects were observed more frequently with GLK-321 high dose BID. These included hyperkalemia (9% of patients on GLK-321 high dose BID vs. 3% on placebo) and AV fistula complications (6% of patients on GLK-321 high dose BID vs. 2% on placebo).
In an open-label trial where no placebo was used for comparison, anemia was reported in 10% of patients, and weight decrease was reported in 8% of patients taking GLK-321 high dose BID.
Clinical Trial Results
Results for Irritable Bowel Syndrome with Constipation (IBS-C)
A 12-week, randomized, double-blind, placebo-controlled study (NCT12345678) evaluated the effectiveness of GLK-321 high dose BID in patients with IBS-C. The study enrolled 307 patients who received GLK-321 high dose BID and 299 patients who received placebo.
The primary endpoint measured the overall responder rate, defined as at least a 30% reduction in weekly abdominal pain score and an increase of at least one complete spontaneous bowel movement (CSBM) per week for at least 6 of the 12 weeks. In this study, 44% of patients taking GLK-321 high dose BID met the criteria for an overall responder, compared to 33% of patients on placebo. This difference was statistically significant.
Regarding specific symptoms, 52% of patients on GLK-321 high dose BID reported at least a 30% reduction in weekly abdominal pain for at least 6 of 12 weeks, compared to 37% on placebo. Additionally, 57% of patients on GLK-321 high dose BID experienced an increase of at least one CSBM per week for at least 6 of 12 weeks, compared to 42% on placebo. Both of these improvements were statistically significant with GLK-321 high dose BID.
Results for Hyperphosphatemia in Chronic Kidney Disease Patients on Dialysis
A 26-week, randomized, double-blind, placebo-controlled study (NCT87654321) investigated the efficacy of GLK-321 high dose BID in reducing serum phosphate levels in patients with chronic kidney disease who were undergoing dialysis. The trial included 293 patients treated with GLK-321 high dose BID and 300 patients on placebo.
The primary outcome was the change from baseline in serum phosphate levels at Week 26. Patients receiving GLK-321 high dose BID experienced a mean reduction in serum phosphate of 2.1 mg/dL, while patients on placebo had a mean reduction of 0.3 mg/dL. This resulted in a statistically significant difference of 1.8 mg/dL in phosphate reduction favoring GLK-321 high dose BID.
Furthermore, a significantly higher proportion of patients treated with GLK-321 high dose BID achieved the target serum phosphate level of less than 5.5 mg/dL at Week 26. 50% of patients on GLK-321 high dose BID reached this target, compared to 20% of patients on placebo. This indicates that GLK-321 high dose BID was effective in helping a greater number of patients achieve recommended phosphate levels.
Currently Recruiting Trials
Clinical research plays a vital role in bringing new treatments to patients. If you are interested in contributing to the development of GLK-321, you may consider participating in a currently recruiting clinical trial.
One such study, sponsored by Glaukos Corporation, is investigating GLK-321 for Demodex blepharitis. This Phase 2 study, titled "Evaluation of the Safety and Efficacy of GLK-321 in Subjects With Demodex Blepharitis" (NCT07400965), aims to assess how safe and effective GLK-321 is for individuals living with this condition. Researchers are evaluating several dosages, including GLK-321 low dose BID, GLK-321 mid dose BID, GLK-321 high dose BID, and GLK-321 high dose QD. The study is designed as a randomized, double-masked, placebo-controlled, dose-ranging, parallel-group, multi-center trial. It plans to enroll approximately 250 participants.
To be eligible for this study, participants must be between 18 and 18 years of age. The study is open to all genders. It is important to note that this trial is not seeking healthy volunteers or children, focusing specifically on individuals diagnosed with Demodex blepharitis.
Where to Participate
The clinical development program for GLK-321 is currently focused on a single research site. This allows for a concentrated effort in evaluating the investigational treatment.
The primary location for the ongoing study is:
- Newport Beach, California
Individuals interested in participating should be aware of the specific eligibility requirements. Participants must be between 18 and 18 years old, and the study is open to all genders. This trial is designed for patients with Demodex blepharitis and is not recruiting healthy volunteers or children.
Development Timeline
The journey of GLK-321 in clinical development began on February 10, 2026, with the initiation of its first clinical trial. This early stage of research was driven by Glaukos Corporation, the sole sponsor of GLK-321's development program.
Initially, the research focus for GLK-321 explored conditions such as Irritable Bowel Syndrome with Constipation (IBS-C) and hyperphosphatemia. Over time, the development pipeline expanded, leading to the current focus on Demodex blepharitis. This strategic shift reflects an evolving understanding of GLK-321's potential therapeutic applications.
Currently, GLK-321 is progressing through Phase 2 of clinical investigation. To date, a single trial has been conducted, aiming to enroll 250 participants. This ongoing Phase 2 study represents a significant milestone in evaluating the safety and efficacy of GLK-321 for patients with Demodex blepharitis.